Stock 4147 TAIMED BIOLOGICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News TaiMed Biologics Inc.

Equities

4147

TW0004147004

End-of-day quote Taipei Exchange
Other stock markets
 23:00:00 14/05/2024 BST 		5-day change 1st Jan Change
86.4 TWD -1.14% Intraday chart for TaiMed Biologics Inc. -0.35% +5.37%
05-10 TaiMed Biologics Inc. Announces Enrollment of the Last Patient in Phase 2a Study of the Long-Acting TMB-365/TMB-380 Mabcombination for the Bi-Monthly Maintenance HIV Therapy CI
03-20 TaiMed Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
TaiMed Biologics Inc. Announces Enrollment of the Last Patient in Phase 2a Study of the Long-Acting TMB-365/TMB-380 Mabcombination for the Bi-Monthly Maintenance HIV Therapy
CI
TaiMed Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Taimed Biologics and AcedrA Biopharmaceticals Partner to Commercialize Trogarzo in the Middle East and North Africa Region
CI
Taimed Announces Its Marketing Partner Received Refusal to File Letter for Trogarzo Intramuscular Method of Administration sBLA from the US FDA
CI
TaiMed Biologics Inc. Receives Patent Approval from the Taiwan Intellectual Property Office for Improving the Pharmacokinetic Performance of TMB-365 Using Histidine Modification Technology
CI
TaiMed Biologics Inc. Announces US FDA Grants Fast Track Designation to TMB-365/TMB-380 Long-Acting Combination Therapy for HIV Infection
CI
TaiMed Biologics Inc. Revises the Phase 2 Clinical Study Design of Bi-Monthly Dosing of TMB-365/TMB-380 Combination for the Treatment of HIV Infection
CI
Taimed Biologics Inc. Announces US FAD Approves the sBLA for the IV Push Administration of the Loading Dose of Trogarzo
CI
TaiMed Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Theratechnologies Reports Results from Trogarzo Intramuscular Administration Study; Tesamorelin Poster Presentation
MT
TaiMed Biologics Inc. Announces Results from Trogarzo Intramuscular (IM) Administration Study
CI
TaiMed Biologics Inc. Completes Data Analysis of the Clinical Trial Sentinel Group for the TMB-365 and TMB-380 Combination as Expected and Confirms the Dosing for Future Execution
CI
TaiMed Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
TaiMed Biologics Inc. Completes the Last Patient Visit of the Sentinel Group in the Clinical Study Evaluating Long-Acting TMB-365/TMB-380 Combination Maintenance Therapy
CI
TaiMed Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
TaiMed Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
TaiMed Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
TaiMed Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
US FDA Approves the Supplemental Biologicslicense Application for Intravenous (IV) Pushadministration of Trogarzo
CI
TaiMed Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4147 Stock
  4. News TaiMed Biologics Inc.